Hood River Capital Management LLC Cerevel Therapeutics Holdings, Inc. Transaction History

Hood River Capital Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$23.9 - $35.38 $215,339 - $318,773	9,010 Added 1.57%	581,886 $18.5 Million
Q1 2023 May 15, 2023	SELL	$22.82 - $35.32 $8 Million - $12.4 Million	-350,762 Reduced 37.98%	572,876 $14 Million
Q4 2022 Feb 14, 2023	BUY	$25.35 - $31.96 $686,123 - $865,029	27,066 Added 3.02%	923,638 $29.1 Million
Q3 2022 Nov 14, 2022	BUY	$25.5 - $41.42 $12.1 Million - $19.6 Million	473,322 Added 111.83%	896,572 $25.3 Million
Q2 2022 Aug 15, 2022	BUY	$20.62 - $37.15 $8.73 Million - $15.7 Million	423,250 New	423,250 $11.2 Million

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Hood River Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Hood River Capital Management LLC with notifications on news.